4/A: MAINZ BIOMED Director Plans 685K Share Purchase

MAINZ BIOMED N.V. Director and 10% Owner Kevin Michael Donahue filed an amendment detailing a planned acquisition of 685,000 shares of common stock at $1.51 per share.

Summary

• Kevin Michael Donahue, a Director and 10% Owner of MAINZ BIOMED N.V. (MYNZ), filed an amended Statement of Changes in Beneficial Ownership (Form 4/A).
• The filing corrects a previous Form 4 filed on January 16, 2026.
• The amendment reports a planned acquisition of 685,000 shares of common stock.
• This transaction is scheduled for October 17, 2025, at a price of $1.51 per share.
• The acquisition is being made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following this planned transaction, Kevin Michael Donahue will beneficially own 685,000 shares of common stock directly.

Sentiment

Score: 8

Explanation: The planned acquisition of a substantial number of shares by a director and 10% owner, especially under a 10b5-1 plan, is a strong positive signal of insider confidence in the company's future value.

Positives

• A Director and 10% Owner planning a significant purchase of 685,000 shares indicates strong confidence in the company's future prospects.
• The planned acquisition under a Rule 10b5-1 plan suggests a pre-meditated investment decision, often viewed favorably by the market.

Future Outlook

The planned insider purchase suggests a positive outlook from a key stakeholder regarding the company's future performance and valuation.

Industry Context

Insider buying, particularly from a director and significant owner, can signal strong internal conviction in a company's trajectory, potentially differentiating it within the competitive biomedical industry.

Related Party Transactions

• Kevin Michael Donahue, a Director and 10% Owner, is planning to acquire 685,000 shares of common stock from the issuer, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this planned insider purchase as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.
• The commitment to a future purchase could signal stability and a long-term perspective from a significant owner.

Key Dates

Recommendation

The planned acquisition of 685,000 shares by a Director and 10% Owner, Kevin Michael Donahue, at $1.51 per share, signals strong insider confidence. This significant commitment, made under a 10b5-1 plan, suggests a belief in the company's future growth and undervaluation. Such a substantial insider purchase is typically a bullish indicator for seasoned investors, warranting a 'buy' recommendation based on this filing alone.

Keywords

MAINZ BIOMED, MYNZ, Insider Buying, Form 4/A, Beneficial Ownership, Director Purchase, 10b5-1 Plan, Equity Acquisition, Biomedical